Skip to Content
Merck
  • Long-term alcohol and caffeine intake and risk of sudden cardiac death in women.

Long-term alcohol and caffeine intake and risk of sudden cardiac death in women.

The American journal of clinical nutrition (2013-04-26)
Monica L Bertoia, Elizabeth W Triche, Dominique S Michaud, Ana Baylin, Joseph W Hogan, Marian L Neuhouser, Matthew S Freiberg, Matthew A Allison, Monika M Safford, Wenjun Li, Yasmin Mossavar-Rahmani, Milagros C Rosal, Charles B Eaton
ABSTRACT

Alcohol and caffeine intakes may play a role in the development of sudden cardiac death (SCD) because of their effects on cholesterol, blood pressure, heart rate variability, and inflammation. Our objective was to examine the association between long-term alcohol and caffeine intakes and risk of SCD in women. We examined 93,676 postmenopausal women who participated in the Women's Health Initiative Observational Study. Women were enrolled between 1993 and 1998 and were followed until August 2009. Women completed a food-frequency questionnaire at baseline and again at year 3. We modeled exposure to alcohol 3 ways: by using baseline intake only, a cumulative average of baseline and year 3 intake, and the most recent reported intake (a simple time-varying analysis). Intake of 5-15 g alcohol/d (about one drink) was associated with a nonsignificantly reduced risk of SCD compared with 0.1-5 g/d of baseline intake (HR: 0.64; 95% CI: 0.40, 1.02), of cumulative average intake (HR: 0.69; 95% CI: 0.43, 1.11), and of most recent intake (HR: 0.58; 95% CI: 0.35, 0.96), with adjustment for age, race, income, smoking, body mass index, physical activity, hormone use, and total energy. No association was found between SCD and total caffeine intake (mg/d) or cups of caffeinated coffee, decaffeinated coffee, and caffeinated tea. Our results suggest that about one drink per day (or 5.1-15 g/d) may be associated with a reduced risk of SCD in this population; however, this association was only statistically significant for a model using the most recent alcohol intake. Total caffeine, regular coffee, decaffeinated coffee, and regular tea intake were not associated with the risk of SCD. This trial was registered at clinicaltrials.gov as NCT00000611.

MATERIALS
Product Number
Brand
Product Description

Supelco
Melting point standard 235-237°C, analytical standard
Supelco
Caffeine solution, analytical standard, 1.0 mg/mL in methanol
Supelco
Caffeine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Caffeine for system suitability, European Pharmacopoeia (EP) Reference Standard
Supelco
Caffeine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
Caffeine Melting Point Standard, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Caffeine, anhydrous, 99%, FCC, FG
Sigma-Aldrich
Caffeine, anhydrous, tested according to Ph. Eur.
Sigma-Aldrich
Caffeine, meets USP testing specifications, anhydrous
Sigma-Aldrich
Caffeine, Sigma Reference Standard, vial of 250 mg
Sigma-Aldrich
Caffeine, powder, ReagentPlus®
Sigma-Aldrich
Caffeine, BioXtra
Supelco
Mettler-Toledo Calibration substance ME 18872, Caffeine, traceable to primary standards (LGC)
Supelco
Caffeine, Pharmaceutical Secondary Standard; Certified Reference Material
Caffeine, European Pharmacopoeia (EP) Reference Standard